Brazil is a major healthcare and pharmaceutical market, but it is also a highly regulated environment. Foreign pharmaceutical companies entering Brazil must coordinate corporate setup, Anvisa requirements, tax registration, accounting, payroll, product registration, imports, pricing, clinical research and compliance controls.
In other words, a pharma market entry project is never just a sales project. It is a regulatory and financial infrastructure project.
Rodrigo Ribeiro, partner at CLM Controller, explains:
“A foreign pharmaceutical company in Brazil needs reliable accounting because every regulatory decision has a financial effect. Product registration, imports, payroll, samples, clinical research and tax credits must be visible in the numbers.”
CLM Controller helps international companies with accounting, tax, payroll, paralegal, audit and financial routines in Brazil.
Learn more at CLM Controller
Why pharma compliance in Brazil is different

Pharmaceutical companies in Brazil deal with different layers of regulation:
– corporate and CNPJ registration;
– Anvisa authorization;
– product registration or regularization;
– good manufacturing or distribution practices;
– import controls;
– clinical research rules;
– tax obligations;
– payroll and labor compliance;
– data protection;
– pricing and commercial controls.
The Brazilian Health Regulatory Agency, Anvisa, is the central authority for medicines, health products, clinical research, pharmacovigilance and several regulated activities. Its official medicines page includes regularized medicine consultation, labels, package inserts, generics, similar medicines, controlled products, clinical research and current legislation.
Source: Anvisa Medicines
Company setup for foreign pharma companies

Foreign pharma groups usually enter Brazil through:
– a local subsidiary;
– an acquisition of a Brazilian company;
– a distribution structure;
– a local representative or importer model;
– a clinical research or R&D presence.
The correct structure depends on whether the company will manufacture, import, distribute, register products, conduct clinical trials, sell to hospitals, sell to distributors or support a local partner.
CNPJ and business registration
A Brazilian legal entity needs a CNPJ to operate, sign contracts, hire employees and comply with tax obligations. Official references include Receita Federal CNPJ, Atualizar CNPJ ou inscrever filial and Redesim.
Choosing the right activity codes
The CNAE codes and corporate purpose must match the real activity. Pharma companies should be careful when defining import, distribution, manufacturing, technical services, research, consulting or commercial representation activities.
Wrong activity classification may delay licenses, tax registration or Anvisa procedures.
Anvisa authorization and regulated activities

Companies that manufacture, distribute, store, transport, import or export regulated products may need authorization from Anvisa. Anvisa’s AFE or AE page specifically refers to authorization for manufacturing, distributing, storing, transporting, importing or exporting.
Source: Anvisa AFE or AE.
AFE and AE
AFE means Autorizacao de Funcionamento de Empresa, or Company Operating Authorization. AE means Special Authorization and may apply to specific controlled activities.
Foreign groups should confirm:
– which Brazilian entity will hold the authorization;
– whether the entity will import or distribute;
– whether a warehouse or logistics provider needs specific authorization;
– whether controlled products are involved;
– whether local technical responsibility is required.
Product registration and regularized medicines

Before selling medicines in Brazil, the company must understand the applicable registration or regularization path. Anvisa provides official consultation for regularized medicines and current medicine legislation through its medicines portal.
Foreign companies should map:
– product category;
– active ingredient;
– reference, generic, similar, biological or advanced therapy classification;
– package insert and labeling requirements;
– manufacturing site;
– stability data;
– local holder of registration;
– import model;
– pharmacovigilance responsibilities.
Good Manufacturing Practices and distribution practices
Anvisa issues Good Practices Certificates. According to Anvisa, the certificate confirms that an establishment complies with procedures and practices established in specific agency rules. It may be a Good Manufacturing Practices Certificate or a Good Distribution and Storage Practices Certificate.
Source: Anvisa Good Practices Certificate.
Why accounting teams must care about GMP
GMP may look purely regulatory, but it affects accounting and finance. It can impact:
– inventory controls;
– batch traceability;
– import costs;
– warehouse contracts;
– quality-related provisions;
– product returns;
– destroyed goods;
– vendor qualification;
– insurance;
– cost of goods sold.
Clinical research in Brazil

If the foreign company conducts clinical research in Brazil, Anvisa states that clinical studies are performed with humans to measure safety and efficacy of new medicines and are divided into phases I, II, III and IV. Anvisa also references RDC 945/2024, RDC 172/2017 and Law 14,874/2024 for different clinical research situations.
Source: Anvisa Clinical Research
The finance team should track:
– clinical trial costs;
– investigator payments;
– CRO agreements;
– import of samples;
– reimbursements;
– taxes on services;
– documentation for audit;
– related-party charges.
Tax and accounting points for pharma companies

Pharma companies need strong monthly accounting because their operations often include imports, inventory, regulated pricing, samples, returns, R&D, intercompany payments and technical services.
Corporate tax regime
Many foreign pharma companies operate under Lucro Real, especially when they have significant revenue, imports, inventory or deductible operating expenses.
Indirect taxes and tax reform
Brazil’s tax reform creates a new consumption tax model with CBS and IBS. Pharmaceutical products may be affected by specific rules, reduced rates or different treatment depending on final regulation. Companies should model transition impacts and ERP readiness using official legislation, including Constitutional Amendment 132/2023.
Transfer pricing and intercompany charges
Foreign pharma companies often have intercompany transactions, such as product imports, royalties, management fees, technical assistance and R&D services. These should be documented and aligned with Brazilian transfer pricing rules.
Monthly compliance package for foreign pharma companies
A practical monthly package should include:
– accounting statements;
– tax calculation summary;
– payroll report;
– inventory and import report;
– intercompany transaction report;
– regulatory fee and authorization status;
– product registration cost tracking;
– clinical research cost tracking;
– cash flow;
– compliance calendar.
How CLM Controller can help

CLM Controller can support foreign pharma companies with:
– company opening and CNPJ;
– accounting outsourcing;
– tax compliance;
– payroll outsourcing;
– financial BPO;
– monthly reports in English;
– support for regulated activity cost controls;
– audit and compliance support;
– coordination with legal and regulatory advisors.
FAQ
1. Does a foreign pharmaceutical company need a Brazilian entity?
Usually, a Brazilian entity is needed when the company wants to import, distribute, hire employees, hold registrations or operate directly in Brazil.
2. What is Anvisa?
Anvisa is Brazil’s health regulatory agency. It regulates medicines, health products, clinical research, good practices and several regulated activities.
3. What is AFE in Brazil?
AFE is the Company Operating Authorization issued by Anvisa for certain regulated activities, such as manufacturing, importing, distributing, storing, transporting or exporting.
4. Are Good Manufacturing Practices important for foreign manufacturers?
Yes. Anvisa’s Good Practices Certificates may be required depending on product type, manufacturing site and regulatory path.
5. Can CLM replace a pharma regulatory consultant?
No. CLM supports accounting, tax, payroll, paralegal and financial compliance. Pharma regulatory work should be handled by specialized regulatory professionals, coordinated with the accounting and tax structure.



0 Comments